Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Viemed Healthcare (VMD) Shares Outstanding (Diluted Average) (2018 - 2025)

Viemed Healthcare (VMD) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $40.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) changed 0.05% year-over-year to $40.8 million, compared with a TTM value of $40.8 million through Dec 2025, changed 0.05%, and an annual FY2025 reading of $40.8 million, changed 0.05% over the prior year.
  • Shares Outstanding (Diluted Average) was $40.8 million for Q4 2025 at Viemed Healthcare, down from $41.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $41.6 million in Q1 2025 and bottomed at $39.8 million in Q4 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $40.6 million, with a median of $40.6 million recorded in 2021.
  • The sharpest move saw Shares Outstanding (Diluted Average) dropped 2.15% in 2022, then rose 2.58% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $40.7 million in 2021, then decreased by 2.15% to $39.8 million in 2022, then rose by 1.44% to $40.4 million in 2023, then grew by 1.06% to $40.8 million in 2024, then grew by 0.05% to $40.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for VMD at $40.8 million in Q4 2025, $41.1 million in Q3 2025, and $41.4 million in Q2 2025.